MedTrace Logo

A Phase I Study of QL1604 for Advanced Solid Tumors

NCT05801094 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2023-04-06

No results posted yet for this study

Summary

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

QL1604

QL1604 3 mg/kg Q3W

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weijian Guo, PhD · Fudan University

  • Jianping Xiong, PhD · The First Affliated Hospital of Nanchang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2023-04-15
Completion
2023-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05801094 on ClinicalTrials.gov